Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
T. Rowe Price Health Sciences Fund
mutual fund
PRHSX
Dividend policy
Active
Price as of:
$101.47
+0.05
+0%
primary theme
Health Care Sector Equity
share class
PRHSX (Mutual Fund)
T. Rowe Price Health Sciences Fund
Dividend policy
Active
Price as of:
$101.47
+0.05
+0%
primary theme
Health Care Sector Equity
share class
PRHSX - Snapshot
Vitals
- YTD Return 24.6%
- 3 Yr Annualized Return 17.4%
- 5 Yr Annualized Return 13.7%
- Net Assets $16.7 B
- Holdings in Top 10 34.0%
52 WEEK LOW AND HIGH
$101.42
$60.38
$101.47
Expenses
OPERATING RELATED FEES
- Expense Ratio 0.76%
SALES FEES
- Front Load N/A
- Deferred Load N/A
BROKERAGE FEES
- Turnover 38.80%
TRADING FEES
- Max Redemption Fee N/A
Min Investment
- Standard (Taxable) $2,500
- IRA $1,000
Fund Classification
- Primary Theme Health Care Sector Equity
- Fund Type Open End Mutual Fund
- Investment Style Health
Overview
Next Dividend
Income Profile
Income Risk
Returns Profile
Allocations
Expenses
About
Dividend.com Ratings*
$109.21
+0.57%
$14.12 B
1.17%
$1.27
blocked
blocked
blocked
13.82%
-
Overview
Next Dividend
Income Profile
Income Risk
Returns Profile
Allocations
Expenses
About
Dividend.com Ratings*
Health Care Select Sector SPDR® Fund
XLV | ETF
$111.49
+0.75%
$24.57 B
1.49%
$1.65
blocked
blocked
blocked
9.32%
-
Vanguard Health Care Index Fund
VHT | ETF
$218.28
+0.49%
$14.12 B
1.17%
$2.55
blocked
blocked
blocked
13.84%
-
iShares Nasdaq Biotechnology ETF
IBB | ETF
$144.99
-0.23%
$9.78 B
0.21%
$0.30
blocked
blocked
blocked
21.52%
-
iShares U.S. Medical Devices ETF
IHI | ETF
$315.37
+0.50%
$8.75 B
0.27%
$0.84
blocked
blocked
blocked
19.03%
-
PRHSX - Profile
Distributions
- YTD Total Return 24.6%
- 3 Yr Annualized Total Return 17.4%
- 5 Yr Annualized Total Return 13.7%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio 0.00%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NameT. Rowe Price Health Sciences Fund
-
Fund Family NameT. Rowe Price
-
Inception DateDec 29, 1995
-
Shares OutstandingN/A
-
Share ClassNo Load
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerZiad Bakri
Fund Description
The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies. It is non-diversified.
PRHSX - Performance
Return Ranking - Trailing
| Period | PRHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 24.6% | -3.6% | 157.0% | 22.36% |
| 1 Yr | 27.9% | 1.8% | 148.1% | 28.83% |
| 3 Yr | 17.4%* | 2.7% | 51.8% | 12.59% |
| 5 Yr | 13.7%* | -0.5% | 34.2% | 13.57% |
| 10 Yr | 20.8%* | 9.6% | 21.4% | 3.25% |
* Annualized
Return Ranking - Calendar
| Period | PRHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2019 | 21.5% | 3.8% | 63.8% | 42.07% |
| 2018 | -4.7% | -49.7% | 21.5% | 37.96% |
| 2017 | 19.1% | -59.8% | 54.4% | 49.63% |
| 2016 | -14.2% | -36.6% | 11.6% | 49.61% |
| 2015 | 1.3% | -62.4% | 27.9% | 33.61% |
Total Return Ranking - Trailing
| Period | PRHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 24.6% | -3.6% | 147.2% | 22.36% |
| 1 Yr | 27.9% | -3.5% | 148.1% | 25.15% |
| 3 Yr | 17.4%* | 1.8% | 51.8% | 12.59% |
| 5 Yr | 13.7%* | -0.5% | 34.2% | 13.57% |
| 10 Yr | 20.8%* | 9.5% | 21.4% | 3.25% |
* Annualized
Total Return Ranking - Calendar
| Period | PRHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2019 | 21.5% | 3.8% | 63.8% | 42.07% |
| 2018 | -4.7% | -25.3% | 22.2% | 45.26% |
| 2017 | 19.1% | -10.8% | 54.4% | 60.74% |
| 2016 | -14.2% | -36.6% | 11.6% | 58.91% |
| 2015 | 1.3% | -16.6% | 27.9% | 66.39% |
NAV & Total Return History
PRHSX - Holdings
Concentration Analysis
| PRHSX | Category Low | Category High | PRHSX % Rank | |
|---|---|---|---|---|
| Net Assets | 16.7 B | 4.64 M | 46 B | 2.91% |
| Number of Holdings | 154 | 24 | 426 | 10.47% |
| Net Assets in Top 10 | 4.84 B | 1.01 M | 19.6 B | 4.65% |
| Weighting of Top 10 | 33.98% | 15.4% | 77.0% | 75.58% |
Top 10 Holdings
- UnitedHealth Group Inc 6.10%
- Thermo Fisher Scientific Inc 4.43%
- Intuitive Surgical Inc 4.24%
- Intuitive Surgical Inc 4.24%
- Intuitive Surgical Inc 4.24%
- Intuitive Surgical Inc 4.24%
- Intuitive Surgical Inc 4.24%
- Intuitive Surgical Inc 4.24%
- Intuitive Surgical Inc 4.24%
- Intuitive Surgical Inc 4.24%
Asset Allocation
| Weighting | Return Low | Return High | PRHSX % Rank | |
|---|---|---|---|---|
| Stocks | 99.26% | 76.86% | 100.05% | 41.28% |
| Other | 0.60% | -1.51% | 10.43% | 23.84% |
| Preferred Stocks | 0.14% | 0.00% | 4.75% | 12.79% |
| Convertible Bonds | 0.00% | 0.00% | 0.05% | 65.70% |
| Cash | 0.00% | -0.28% | 12.53% | 88.37% |
| Bonds | 0.00% | 0.00% | 16.11% | 66.28% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | PRHSX % Rank | |
|---|---|---|---|---|
| Healthcare | 99.41% | 61.64% | 100.00% | 54.07% |
| Basic Materials | 0.53% | 0.00% | 3.14% | 20.35% |
| Financial Services | 0.05% | 0.00% | 3.21% | 30.23% |
| Utilities | 0.00% | 0.00% | 0.00% | 64.53% |
| Technology | 0.00% | 0.00% | 15.86% | 70.93% |
| Real Estate | 0.00% | 0.00% | 6.03% | 68.02% |
| Industrials | 0.00% | 0.00% | 5.94% | 68.60% |
| Energy | 0.00% | 0.00% | 0.00% | 64.53% |
| Communication Services | 0.00% | 0.00% | 4.69% | 66.86% |
| Consumer Defense | 0.00% | 0.00% | 33.59% | 68.02% |
| Consumer Cyclical | 0.00% | 0.00% | 1.21% | 68.02% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | PRHSX % Rank | |
|---|---|---|---|---|
| US | 86.89% | 56.70% | 99.99% | 27.33% |
| Non US | 12.37% | 0.00% | 43.24% | 58.14% |
PRHSX - Expenses
Operational Fees
| PRHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.76% | 0.08% | 25.14% | 70.48% |
| Management Fee | 0.64% | 0.00% | 1.25% | 51.16% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | 4.17% |
| Administrative Fee | 0.15% | 0.03% | 0.40% | 75.00% |
Sales Fees
| PRHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| PRHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| PRHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 38.80% | 0.70% | 252.00% | 53.37% |
PRHSX - Distributions
Dividend Yield Analysis
| PRHSX | Category Low | Category High | PRHSX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 3.15% | 72.67% |
Dividend Distribution Analysis
| PRHSX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Net Income Ratio Analysis
| PRHSX | Category Low | Category High | PRHSX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | 0.00% | -2.53% | 2.53% | 49.70% |
Capital Gain Distribution Analysis
| PRHSX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
PRHSX - Fund Manager Analysis
Managers
Ziad Bakri
Start Date
Tenure
Tenure Rank
Apr 01, 2016
4.67
4.7%
Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment banking analyst positions in other investment firms
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.17 | 23.22 | 7.36 | 20.6 |
